Health Condition 1: null- Alcoholic Liver Disease with Intra Hepatic Cholestasis
Conditions
Interventions
Intervention1: Heptral: Generic Name: Ademetionine or S-adenosyl-L-methionine
Dose & Frequency: As per approved labeled recommendations
Duration: Minimum of 6 weeks, can be extended if required base
Sponsors
Abbott India Limited
Eligibility
Inclusion criteria
Inclusion criteria: 1) Chronic liver disease due to alcoholic liver disease as diagnosed by the physician 2) Intrahepatic cholestasis as diagnosed by the physician 3) Age 18 to 65 years. 4) Patients being prescribed Heptral according to local label. 5) Patient?s written authorization to provide data for the study.
Exclusion criteria
Exclusion criteria: 1) Contraindications to Heptral treatment including hypersensitivity according to the local label. 2) Pregnancy 1-2 trimester or lactation. 3) Hepatocellular or metastatic liver carcinoma. 4) Severe liver disease including but not limited to ascites, hepatic encephalopathy, hypoalbuminemia, coagulopathy. 5) Other conditions that make the patients participation impossible (by investigator judgment). 6) Patients receiving any hepatotoxic medications
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| 1. Demographic data underlying liver disease, diagnostic criteria of intrahepatic cholestasis. 2. Burden of disease in terms of Healthcare utilization & Workload effect 3. Reason(s) for prescribing HeptralTimepoint: After 6 weeks of therapy | — |
Secondary
| Measure | Time frame |
|---|---|
| To better understand the effectiveness and the tolerability of ademetionine therapy in the patient population with cholestasis in chronic liver disease due to alcoholic liver disease.Timepoint: 6 weeks treatment | — |
Countries
India
Contacts
Public ContactDr Tina Singh
Abbott India Limited
Outcome results
None listed